Quantum BioPharma Ltd. (NASDAQ: QNTM) reported unaudited financial and operational results for the third quarter ended Sept. 30, 2026, revealing a significantly strengthened balance sheet and advancement of its lead clinical program. The company’s cash and cash equivalents totaled approximately $3.56 million, while digital assets reached $8.66 million, representing combined holdings of $12.22 million, compared with $4.12 million at year-end 2025, excluding restricted digital assets. This improvement in liquidity underscores the company’s ability to fund its planned operations over the next 12 months, as stated by management.
Shareholders’ equity increased 91% to $9.77 million, and working capital rose to $5.47 million from $420,000, reflecting a substantial enhancement in financial flexibility. Third-quarter operating expenses declined 24% year over year to $3.56 million, and the nine-month net loss narrowed 26% to $17.32 million from $23.25 million. Quantum also reported a 21% reduction in operating cash use for the first nine months of 2026 and a decrease in notes payable to $300,000 following repayment of $1 million in debt. These metrics indicate a disciplined approach to cost management and balance sheet strengthening.
The financial improvements come as Quantum advances its clinical development program. Following quarter-end, the company entered into a study start-up agreement with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-MS for progressive multiple sclerosis. This agreement follows U.S. Food and Drug Administration clearance of the company’s Investigational New Drug application in August 2026. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The Phase 2 trial is a critical step toward potential regulatory approval and commercialization.
For investors seeking detailed information, the full press release is available at https://ibn.fm/GJ1ER. Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum focuses on the research and development of Lucid-MS. The company also invented UNBUZZD™ and retains ownership of 19.84% of Unbuzzd Wellness Inc., with royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity.
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. This announcement matters because it demonstrates Quantum’s improved financial health and its progression toward a Phase 2 trial for a potentially transformative multiple sclerosis treatment. The combination of increased liquidity, reduced expenses, and clinical advancement positions the company to pursue its strategic goals without immediate financing concerns. For a sector often challenged by capital constraints, Quantum’s ability to grow its cash and digital asset holdings while narrowing losses is a notable achievement. The agreement with Thermo Fisher Scientific further validates the company’s clinical strategy and provides access to world-class research infrastructure. As Quantum moves closer to testing Lucid-MS in patients, the implications for progressive multiple sclerosis treatment could be significant, given the unmet medical need. Investors and industry observers will be watching closely as the Phase 2 trial progresses.
InvestorWire, a specialized communications platform, distributes such press releases and provides editorial syndication to 5,000+ outlets, enhancing visibility for companies like Quantum BioPharma. For more information on InvestorWire’s services, including press release enhancement and social media distribution, visit their website. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer.


